menu
Increasing various research activities is propelling growth of the pediatric vaccines market
Increasing various research activities is propelling growth of the pediatric vaccines market
Growing awareness regarding vaccines and immunization among the populace is propelling the growth of the global pediatric vaccines market.

Growing awareness regarding vaccines and immunization among the populace is propelling the growth of the global pediatric vaccines market. For example, in the U.S., the month of January is celebrated as Cervical Health Awareness Month, wherein the importance of regular vaccination and screening in the prevention of cancer is forwarded. Also, increasing incidences of invasive cervical cancer are again anticipated to foster the growth of the market. According to the American Cancer Society, about 13,800 new cases of invasive cervical cancer are expected to be diagnosed in the U.S. in 2020 and the disease is expected to lead to the death of 4,290 women in the same year. The American Academy of Pediatrics recommends HPV vaccination for both females and males between the ages of 9 and 12, as vaccinations are more effective before any exposure to the virus.

In December 2019, Soligenix, Inc. initiated the study to assess the Safety of RiVax, a lyophilized ricin toxin A-chain subunit vaccine with alum-adjuvant

In April 2018, Merck & Co, Inc. initiated two Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.

On the other hand, low accessibility of vaccines to remote areas is expected to restrict the growth of the pediatric vaccine market. For instance, according to the World Health Organization in 2018, around 19.4 million children under the age of one year did not receive basic vaccines. Around 60% of these children belonged to emerging countries such as Angola, Brazil, the Democratic Republic of the Congo, Ethiopia, India, Indonesia, Nigeria, Pakistan, the Philippines, and Viet Nam.

North America is expected to dominate the global pediatric vaccines market and this is accredited to increasing FDA approval for introducing novel vaccines in the region. For instance, in December 2019, NewLink Genetics Corporation received the U.S. FDA approval for ERVEBO or Zaire Ebola virus vaccine V920.

Pediatric vaccines protect children from infectious agents like viruses, bacteria, and fungi that can cause serious diseases like smallpox, measles, mumps, and chickenpox. They also prevent diseases caused by these agents in adults. Vaccines are mostly made to protect against diseases that spread through mosquitoes. This includes yellow fever, dengue, and malaria. A pediatric vaccine, usually given to infants below 6 years of age, is the rotavirus. An important part of the routine schedule of vaccinations is the rotavirus vaccine, given in two doses along with the other required doses of a diphtheria-to vaccine or a varicella-zoster vaccine.

Read More @ https://digitalinsightscmi-blog.blogspot.com/2021/07/increasing-various-research-activities_20.html